BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Heebøll S, Thomsen KL, Clouston A, Sundelin EI, Radko Y, Christensen LP, Ramezani-moghadam M, Kreutzfeldt M, Pedersen SB, Jessen N, Hebbard L, George J, Grønbæk H. Effect of resveratrol on experimental non-alcoholic steatohepatitis. Pharmacological Research 2015;95-96:34-41. [DOI: 10.1016/j.phrs.2015.03.005] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 3.4] [Reference Citation Analysis]
Number Citing Articles
1 Domitrović R, Potočnjak I. A comprehensive overview of hepatoprotective natural compounds: mechanism of action and clinical perspectives. Arch Toxicol 2016;90:39-79. [DOI: 10.1007/s00204-015-1580-z] [Cited by in Crossref: 50] [Cited by in F6Publishing: 44] [Article Influence: 7.1] [Reference Citation Analysis]
2 Wan S, Zhang L, Quan Y, Wei K. Resveratrol-loaded PLGA nanoparticles: enhanced stability, solubility and bioactivity of resveratrol for non-alcoholic fatty liver disease therapy. R Soc Open Sci 2018;5:181457. [PMID: 30564426 DOI: 10.1098/rsos.181457] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 9.8] [Reference Citation Analysis]
3 Heebøll S, El-Houri RB, Hellberg YE, Haldrup D, Pedersen SB, Jessen N, Christensen LP, Grønbaek H. Effect of resveratrol on experimental non-alcoholic fatty liver disease depends on severity of pathology and timing of treatment. J Gastroenterol Hepatol 2016;31:668-75. [PMID: 26312773 DOI: 10.1111/jgh.13151] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
4 Shamseddin A, Crauste C, Durand E, Villeneuve P, Dubois G, Durand T, Vercauteren J, Veas F. Resveratrol formulated with a natural deep eutectic solvent inhibits active matrix metalloprotease-9 in hormetic conditions: Resveratrol NADES formulation and hormesis. Eur J Lipid Sci Technol 2017;119:1700171. [DOI: 10.1002/ejlt.201700171] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 3.2] [Reference Citation Analysis]
5 Wang C, Duan X, Sun X, Liu Z, Sun P, Yang X, Sun H, Liu K, Meng Q. Protective effects of glycyrrhizic acid from edible botanical glycyrrhiza glabra against non-alcoholic steatohepatitis in mice. Food Funct 2016;7:3716-23. [DOI: 10.1039/c6fo00773b] [Cited by in Crossref: 19] [Cited by in F6Publishing: 4] [Article Influence: 3.2] [Reference Citation Analysis]
6 Bayoumi A, Grønbæk H, George J, Eslam M. The Epigenetic Drug Discovery Landscape for Metabolic-associated Fatty Liver Disease. Trends Genet 2020;36:429-41. [PMID: 32396836 DOI: 10.1016/j.tig.2020.03.003] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 8.5] [Reference Citation Analysis]
7 Li MH, Chen W, Wang LL, Sun JL, Zhou L, Shi YC, Wang CH, Zhong BH, Shi WG, Guo ZW. RLA8—A New and Highly Effective Quadruple PPAR- α / γ / δ and GPR40 Agonist to Reverse Nonalcoholic Steatohepatitis and Fibrosis. J Pharmacol Exp Ther 2019;369:67-77. [DOI: 10.1124/jpet.118.255216] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
8 Koushki M, Amiri-Dashatan N, Ahmadi N, Abbaszadeh HA, Rezaei-Tavirani M. Resveratrol: A miraculous natural compound for diseases treatment. Food Sci Nutr 2018;6:2473-90. [PMID: 30510749 DOI: 10.1002/fsn3.855] [Cited by in Crossref: 48] [Cited by in F6Publishing: 42] [Article Influence: 12.0] [Reference Citation Analysis]
9 Trepiana J, Milton-Laskibar I, Gómez-Zorita S, Eseberri I, González M, Fernández-Quintela A, Portillo MP. Involvement of 5'-Activated Protein Kinase (AMPK) in the Effects of Resveratrol on Liver Steatosis. Int J Mol Sci 2018;19:E3473. [PMID: 30400630 DOI: 10.3390/ijms19113473] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
10 Sharma N, Sircar A, Anders HJ, Gaikwad AB. Crosstalk between kidney and liver in non-alcoholic fatty liver disease: mechanisms and therapeutic approaches. Arch Physiol Biochem 2020;:1-15. [PMID: 32223569 DOI: 10.1080/13813455.2020.1745851] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
11 Wan T, Wang S, Ye M, Ling W, Yang L. Cyanidin-3-O-β-glucoside protects against liver fibrosis induced by alcohol via regulating energy homeostasis and AMPK/autophagy signaling pathway. Journal of Functional Foods 2017;37:16-24. [DOI: 10.1016/j.jff.2017.07.033] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
12 Pasquel D, Doricakova A, Li H, Kortagere S, Krasowski MD, Biswas A, Walton WG, Redinbo MR, Dvorak Z, Mani S. Acetylation of lysine 109 modulates pregnane X receptor DNA binding and transcriptional activity. Biochim Biophys Acta 2016;1859:1155-69. [PMID: 26855179 DOI: 10.1016/j.bbagrm.2016.01.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
13 Xu D, Zhang H, Wang X. Effects of tin caulis dendrobium polysaccharide on the prevention of non-alcoholic fatty liver disease in rats. R Bras Zootec 2017;46:652-6. [DOI: 10.1590/s1806-92902017000800004] [Cited by in Crossref: 3] [Article Influence: 0.6] [Reference Citation Analysis]
14 Daniels SJ, Leeming DJ, Detlefsen S, Bruun MF, Hjuler ST, Henriksen K, Hein P, Krag A, Karsdal MA, Nielsen MJ, Brockbank S, Cruwys S. Addition of trans fat and alcohol has divergent effects on atherogenic diet-induced liver injury in rodent models of steatohepatitis. Am J Physiol Gastrointest Liver Physiol 2020;318:G410-8. [PMID: 31905026 DOI: 10.1152/ajpgi.00066.2019] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Christensen CU, Glavind E, Thomsen KL, Kim YO, Heebøll S, Schuppan D, Hamilton-Dutoit S, Würtz Heegaard C, Grønbæk H. Niemann-Pick type C2 protein supplementation in experimental non-alcoholic fatty liver disease. PLoS One 2018;13:e0192728. [PMID: 29522534 DOI: 10.1371/journal.pone.0192728] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
16 Musso G, Cassader M, Cohney S, Pinach S, Saba F, Gambino R. Emerging Liver-Kidney Interactions in Nonalcoholic Fatty Liver Disease. Trends Mol Med. 2015;21:645-662. [PMID: 26432021 DOI: 10.1016/j.molmed.2015.08.005] [Cited by in Crossref: 56] [Cited by in F6Publishing: 51] [Article Influence: 9.3] [Reference Citation Analysis]
17 Higarza SG, Arboleya S, Gueimonde M, Gómez-Lázaro E, Arias JL, Arias N. Neurobehavioral dysfunction in non-alcoholic steatohepatitis is associated with hyperammonemia, gut dysbiosis, and metabolic and functional brain regional deficits. PLoS One 2019;14:e0223019. [PMID: 31539420 DOI: 10.1371/journal.pone.0223019] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
18 Weiskirchen S, Weiskirchen R. Resveratrol: How Much Wine Do You Have to Drink to Stay Healthy? Adv Nutr 2016;7:706-18. [PMID: 27422505 DOI: 10.3945/an.115.011627] [Cited by in Crossref: 111] [Cited by in F6Publishing: 90] [Article Influence: 18.5] [Reference Citation Analysis]
19 Duan X, Meng Q, Wang C, Liu Z, Liu Q, Sun H, Sun P, Yang X, Huo X, Peng J, Liu K. Calycosin attenuates triglyceride accumulation and hepatic fibrosis in murine model of non-alcoholic steatohepatitis via activating farnesoid X receptor. Phytomedicine 2017;25:83-92. [PMID: 28190475 DOI: 10.1016/j.phymed.2016.12.006] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
20 Badolati N, Masselli R, Sommella E, Sagliocchi S, Di Minno A, Salviati E, Campiglia P, Dentice M, Tenore GC, Stornaiuolo M, Novellino E. The Hepatoprotective Effect of Taurisolo, a Nutraceutical Enriched in Resveratrol and Polyphenols, Involves Activation of Mitochondrial Metabolism in Mice Liver. Antioxidants (Basel) 2020;9:E410. [PMID: 32403305 DOI: 10.3390/antiox9050410] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
21 Daniels SJ, Leeming DJ, Detlefsen S, Bruun MF, Hjuler ST, Henriksen K, Hein P, Karsdal MA, Brockbank S, Cruwys S. Biochemical and histological characterisation of an experimental rodent model of non-alcoholic steatohepatitis – Effects of a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist and a glucagon-like peptide-1 analogue. Biomedicine & Pharmacotherapy 2019;111:926-33. [DOI: 10.1016/j.biopha.2018.12.130] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
22 Ding S, Jiang J, Zhang G, Bu Y, Zhang G, Zhao X. Resveratrol and caloric restriction prevent hepatic steatosis by regulating SIRT1-autophagy pathway and alleviating endoplasmic reticulum stress in high-fat diet-fed rats. PLoS One. 2017;12:e0183541. [PMID: 28817690 DOI: 10.1371/journal.pone.0183541] [Cited by in Crossref: 78] [Cited by in F6Publishing: 77] [Article Influence: 15.6] [Reference Citation Analysis]
23 Chen K, Zhao H, Shu L, Xing H, Wang C, Lu C, Song G. Effect of resveratrol on intestinal tight junction proteins and the gut microbiome in high-fat diet-fed insulin resistant mice. Int J Food Sci Nutr 2020;71:965-78. [PMID: 32306796 DOI: 10.1080/09637486.2020.1754351] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
24 Wang P, Wang J, Li D, Ke W, Chen F, Hu X. Targeting the gut microbiota with resveratrol: a demonstration of novel evidence for the management of hepatic steatosis. J Nutr Biochem 2020;81:108363. [PMID: 32388250 DOI: 10.1016/j.jnutbio.2020.108363] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 7.5] [Reference Citation Analysis]
25 Heebøll S, Kreuzfeldt M, Hamilton-Dutoit S, Kjær Poulsen M, Stødkilde-Jørgensen H, Møller HJ, Jessen N, Thorsen K, Kristina Hellberg Y, Bønløkke Pedersen S, Grønbæk H. Placebo-controlled, randomised clinical trial: high-dose resveratrol treatment for non-alcoholic fatty liver disease. Scand J Gastroenterol 2016;51:456-64. [PMID: 26784973 DOI: 10.3109/00365521.2015.1107620] [Cited by in Crossref: 73] [Cited by in F6Publishing: 73] [Article Influence: 12.2] [Reference Citation Analysis]
26 Aguirre L, Palacios-Ortega S, Fernández-Quintela A, Hijona E, Bujanda L, Portillo MP. Pterostilbene Reduces Liver Steatosis and Modifies Hepatic Fatty Acid Profile in Obese Rats. Nutrients 2019;11:E961. [PMID: 31035507 DOI: 10.3390/nu11050961] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
27 Ji G, Wang Y, Deng Y, Li X, Jiang Z. Resveratrol ameliorates hepatic steatosis and inflammation in methionine/choline-deficient diet-induced steatohepatitis through regulating autophagy. Lipids Health Dis. 2015;14:134. [PMID: 26498332 DOI: 10.1186/s12944-015-0139-6] [Cited by in Crossref: 38] [Cited by in F6Publishing: 41] [Article Influence: 5.4] [Reference Citation Analysis]